Updated hourlyHourly refreshWed, Oct 28, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare · Biotech & pharma
- ASP2138's advancement into Phase 3 marks an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets - TOKYO, Aug. 24, 2026 -- Astellas Pharma Inc. (TSE: 4503,...
Aug 24 · 23:30·PR Newswire
Healthcare · Biotech & pharma
IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood...
Aug 24 · 23:12·PR Newswire
Healthcare · Biotech & pharma
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICESVancouver, British Columbia--(August 24, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta...
Aug 24 · 22:42·Newsfile
Healthcare · Energy
Toronto, Ontario--(August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering"), pursuant to which the Company issued 14,812,500...
Aug 24 · 21:01·Newsfile
Finance · AI
Vancouver, British Columbia, Aug. 24, 2026 -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI” or the “Company”) announces that it has granted an aggregate 24,000 stock options, exercisable at $0.70 per share and valid for a term of three years, and an aggregate 276,053 restricted share units, valid for a term between one to three years, to consultants of the Company and its subsidiary. The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and 96,000 restricted share units and all stock options are subject to vesting over one year. All securities are subject to a hold period of four months and one day in accordance with applicable securities laws and policies of the Canadian Securities Exchange.
About Rocket Doctor AI Inc.
Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.
Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 750,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered.
To learn more about Rocket Doctor AI Inc’s products and services, contact:
www.rocketdoctor.ai or email: info@rocketdoctor.ai
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Rocket Doctor AI
essam.hamza@rocketdoctor.ai
Dr. Bill Cherniak, CEO, Rocket Doctor Inc.
bill@rocketdoctor.io
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321
Cautionary Statements
This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the granting of stock options and restricted share units to consultants, the terms and vesting conditions of such stock options and restricted share units, and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include the risk that the stock options or restricted share units may not vest on the anticipated terms, risks related to the Company’s share compensation plan, and other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
Aug 24 · 21:00·GlobeNewswire
Finance · Healthcare
VAUGHAN, Ontario, August 24, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.
Aug 24 · 20:30·Business Wire
Healthcare
This milestone brings complex cardiothoracic surgical care closer to home for patients in Hernando County and surrounding communities, backed by the expertise and resources of Tampa General's academic health system. TAMPA, Fla., Aug. 24, 2026 -- Tampa General Hospital (TGH)...
Aug 24 · 20:19·PR Newswire
Finance · Healthcare
YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
Aug 24 · 20:05·Business Wire
Healthcare
NEW YORK, Aug. 24, 2026 -- Dimora Medical, a continuous innovator in high-end medical care supplies, today announced price reductions across its entire MegaSorb™ wound dressing lineup—with select SKUs discounted by up to 29% to make advanced wound management solutions more...
Aug 24 · 17:50·PR Newswire
Finance · Healthcare
NEW YORK, Aug. 24, 2026 -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) securities between January 13, 2025 through January 29, 2026,, inclusive (the “Class Period”).
Aug 24 · 17:37·GlobeNewswire
Finance · Healthcare
San Diego, California--(August 24, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company...
Aug 24 · 17:01·Newsfile
Healthcare
New York, NY – August 24, 2026 – In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National […]
Aug 24 · 17:00·iCrowdNewswire